Targeting Triple Negative Breast Cancer With Oncolytic Adenoviruses

Area of Science:

• Oncolytic virotherapy
• Cancer immunology
• Breast cancer therapeutics

Background:

• Breast cancer (BC) is a leading cause of cancer death globally.
• Triple-negative breast cancer (TNBC) lacks effective targeted therapies and has a poor prognosis.
• Current TNBC treatments face challenges with resistance and limited efficacy.

Purpose of the Study:

• To review the potential of oncolytic adenoviruses (OAds) as a novel therapeutic strategy for TNBC.
• To evaluate OAds efficacy in preclinical and clinical settings, alone and in combination therapies.
• To discuss OAds' mechanisms, limitations, and future directions for improving patient outcomes.

Main Methods:

• Review of preclinical studies on OAds in TNBC cell lines and xenografts.
• Analysis of clinical trial data for OAds in various cancers, including breast cancer.
• Examination of OAds combined with standard treatments, targeted agents (EGFR, AR, PARP inhibitors), and immunotherapies.

Main Results:

• OAds demonstrate selective tumor lysis and immune response recruitment in TNBC models.
• Combinations of OAds with PARP inhibitors (e.g., Olaparib) show enhanced anti-tumor effects.
• OAds combined with immune checkpoint inhibitors or cytokine expression show promising results.

Conclusions:

• OAds represent a promising new therapeutic avenue for TNBC and other breast cancers.
• Combination strategies significantly enhance OAds' anti-tumor activity and therapeutic potential.
• Further research is needed to optimize OAds for metastatic disease, immune activation, and intratumoral spread.